239 related articles for article (PubMed ID: 28651117)
41. Emerging therapy for the treatment of mantle cell lymphoma.
Rajguru S; Kahl BS
J Natl Compr Canc Netw; 2014 Sep; 12(9):1311-8; quiz 1318. PubMed ID: 25190697
[TBL] [Abstract][Full Text] [Related]
42. Personalized approaches for treatment-naïve mantle cell lymphoma.
Qualls D; Kumar A
Expert Rev Hematol; 2023 Feb; 16(2):95-107. PubMed ID: 36748785
[TBL] [Abstract][Full Text] [Related]
43. Current treatment approaches for mantle-cell lymphoma.
Witzig TE
J Clin Oncol; 2005 Sep; 23(26):6409-14. PubMed ID: 16155027
[TBL] [Abstract][Full Text] [Related]
44. Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
Kahl BS; Dreyling M; Gordon LI; Martin P; Quintanilla-Martinez L; Sotomayor EM
Leuk Lymphoma; 2019 Aug; 60(8):1853-1865. PubMed ID: 30696305
[TBL] [Abstract][Full Text] [Related]
45. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
[TBL] [Abstract][Full Text] [Related]
46. Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches.
Silkenstedt E; Dreyling M
Hematol Oncol; 2023 Jun; 41 Suppl 1():36-42. PubMed ID: 37294961
[TBL] [Abstract][Full Text] [Related]
47. Management of relapsed mantle cell lymphoma: still a treatment challenge.
Ruan J; Coleman M; Leonard JP
Oncology (Williston Park); 2009 Jul; 23(8):683-90. PubMed ID: 19711582
[TBL] [Abstract][Full Text] [Related]
48. [Analysis of Clinical Characteivstics and Therapeutic Efticacy of 54 Patients with Mantle Cell Lymphoma].
Yang P; Liu YY; An R; Zhen JF; Pang M; Zhao W; Hu K; Wan W; Ke XY; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1336-1342. PubMed ID: 30295247
[TBL] [Abstract][Full Text] [Related]
49. Recent advances in the management of mantle cell lymphoma.
Rivera-Rodriguez N; Cabanillas F
Curr Opin Oncol; 2013 Nov; 25(6):716-21. PubMed ID: 24076580
[TBL] [Abstract][Full Text] [Related]
50. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.
Shah BD; Martin P; Sotomayor EM
Cancer Control; 2012 Jul; 19(3):227-35. PubMed ID: 22710898
[TBL] [Abstract][Full Text] [Related]
51. Current trials for frontline therapy of mantle cell lymphoma.
Steiner RE; Romaguera J; Wang M
J Hematol Oncol; 2018 Jan; 11(1):13. PubMed ID: 29374487
[TBL] [Abstract][Full Text] [Related]
52. Update on mantle cell lymphoma.
Maddocks K
Blood; 2018 Oct; 132(16):1647-1656. PubMed ID: 30154113
[TBL] [Abstract][Full Text] [Related]
53. Mantle cell lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJ; Dreyling M
Crit Rev Oncol Hematol; 2012 Apr; 82(1):78-101. PubMed ID: 21658968
[TBL] [Abstract][Full Text] [Related]
54. Clinical Management Updates in Mantle Cell Lymphoma.
Chen R; Sanchez J; Rosen ST
Oncology (Williston Park); 2016 Apr; 30(4):353-60. PubMed ID: 27083466
[TBL] [Abstract][Full Text] [Related]
55. Diffuse aggressive lymphoma.
Fisher RI; Miller TP; O'Connor OA
Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
[TBL] [Abstract][Full Text] [Related]
56. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment.
Hoster E; Pott C
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):437-445. PubMed ID: 27913513
[TBL] [Abstract][Full Text] [Related]
57. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
58. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
Nastoupil LJ; Koff JL; Flowers CR
Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
[TBL] [Abstract][Full Text] [Related]
59. Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma.
Ruan J
Hematol Oncol Clin North Am; 2020 Oct; 34(5):871-885. PubMed ID: 32861284
[TBL] [Abstract][Full Text] [Related]
60. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Eskelund CW; Kolstad A; Jerkeman M; Räty R; Laurell A; Eloranta S; Smedby KE; Husby S; Pedersen LB; Andersen NS; Eriksson M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Workman CT; Garde C; Elonen E; Brown P; Grønbaek K; Geisler CH
Br J Haematol; 2016 Nov; 175(3):410-418. PubMed ID: 27378674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
